TITLE

News

AUTHOR(S)
Kaye, Donald
PUB. DATE
January 2004
SOURCE
Clinical Infectious Diseases;1/1/2004, Vol. 38 Issue 1, pii
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article presents various news items related to infectious diseases, as of January 1, 2004. The U.S. Food and Drug Administration, in final guidelines to the pharmaceutical industry, said it wants companies to provide that information as part of their applications for approval to antibiotics for food producing animals, such as cows and chickens. Treatment of Alzheimer's disease with 2 antibiotics, doxycycline and rifampin, may lead to cognitive decline in patients.
ACCESSION #
11791879

 

Related Articles

  • The Marketing of Fixed Combination Pharmaceuticals. Faigel, Harris C. // Clinical Pediatrics;Jan1970, Vol. 9 Issue 1, p1 

    Comments on the marketing of fixed combination of pharmaceuticals in the United States. Arguments against fixed-ratio combinations of antibiotics; Application of fixed-ratios in birth control pills, but not in the treatment of infectious diseases; Disagreement between the Pharmaceutical...

  • The Gendered Imagination of Property in Sixteenth- and Seventeenth-Century English Women's Verse. Hammons, Pamela S. // Clio;Summer2005, Vol. 34 Issue 4, p395 

    The article investigates the relations between subjects and objects, and the specific inquiry into women's relations to property, especially real property, by focusing on early women's self-figurations as subjects of property in their poetry. Male-authored texts are examined on how they portray...

  • CNS News Round-Up.  // PharmaWatch: CNS;Sep2010, Vol. 9 Issue 9, p2 

    The article offers world news briefs related to the pharmaceutical industry. The U.S. Food and Drug Administration (FDA) has approved Aricept 23 milligram once-daily tablets for the treatment of Alzheimer's disease. The marketing authorization application for OraVerse, a local anesthesia...

  • Pharmaceuticals.  // ICIS Chemical Business Americas;10/23/2006, Vol. 270 Issue 15, p32 

    The article offers news briefs related to the pharmaceuticals industry. Eisai and Pfizer's Aricept for the treatment of Alzheimer's disease has been approved by the U.S. Food and Drug Administration. Akzo Nobel announced that a drug under development for schizophrenia, asenapine, could be...

  • First drug approved for severe Alzheimer's. LoBuono, Charlotte // Drug Topics;11/17/2003, Vol. 147 Issue 22, p24 

    Reports on the U.S. Food and Drug Administration's approval of memantine for the treatment of moderate to severe Alzheimer's disease. Inhibition of excitotoxic effect by binding preferentially to N-methyl-D-aspartate receptors and blocking cation channels; Common adverse effects;...

  • Lupin wins FDA tentative approval for Alzheimer's drug.  // PharmaWatch: CNS;Mar2010, Vol. 9 Issue 3, p7 

    No abstract available.

  • Higher Dosage Of Aricept OK'd.  // Chain Drug Review;8/30/2010, Vol. 32 Issue 14, p33 

    The article reports on the approval of Aricept, a dopaminergic for the treatment of Alzheimer's diseases, comarketed by Eisai Inc. and Pfizer Inc., by the U.S. Food and Drug Administration (FDA).

  • FDA/EMA ROUNDUP.  // MondayMorning;3/18/2013, Vol. 21 Issue 10, p1 

    The article discusses news briefs related to pharmaceutical industry. Approval of an imaging drug for locating lymph nodes in breast cancer and skin cancer patients is won by Navidea Biopharmaceuticals Inc. Various diabetes drugs are being scrutinized by the U.S. for their potential risk of...

  • Wockhardt wins FDA tentative approval for Alzheimer's drug.  // PharmaWatch: CNS;Feb2010, Vol. 9 Issue 2, p5 

    The article reports that Indian biotechnology company Wockhardt Ltd.'s memantine HCI tablets, an Alzheimer's disease and dementia drug, has received tentative approval from the U.S. Food and Drug Administration (FDA). It mentions that memantine is marketed in the U.S. by Forrest Laboratories...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics